← Leaderboards
Joji Suzuki
Brigham And Women'S Hospital
$3,811,096
Attributed
$4,374,201
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,374,201 · 8
By mechanism
R21$3,375,201 · 7
K23$999,000 · 1
Top collaborators
- Peter R Chai4 shared
- Charlotte Goldfine2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Peter R Chai$5,626,740
- Charlotte Goldfine$358,145
Others in their field
Other Emerging Leaders on “Participant”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$102,389,765
- Scott Topper · Broad Institute, Inc.$101,052,360
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
Research focus
ParticipantDesignOpioid Use DisorderPharmaceutical PreparationsReportingPublic HealthSecondary OutcomePrimary OutcomeNational Institute Of Drug AbuseMortalityRandomizedMonitorCravingAddictionBuprenorphineIntravenousOpioid UseHospitalsAccident And Emergency DepartmentInnovationIncidenceAreaBuprenorphine TreatmentFunding
Grant awards (17)
Extended release buprenorphine as a novel low-dose induction strategy$260,775
R21 · FY2025 · DA · contact PI
Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trial$492,250
R21 · FY2024 · DA · contact PI
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department$268,500
R21 · FY2024 · DA · contact PI
Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorder$265,102
R21 · FY2024 · DA · contact PI
Extended release buprenorphine as a novel low-dose induction strategy$235,542
R21 · FY2024 · DA · contact PI
Oral complications from sublingual buprenorphine treatment: A prospective cohort study$419,819
R21 · FY2023 · DE · contact PI
Developing and pilot testing a novel remotely delivered intensive outpatient program for individuals with opioid use disorder hospitalized with serious injection-related infections$319,323
R21 · FY2023 · DA · contact PI
Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorder$235,191
R21 · FY2023 · DA · contact PI
Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency department$223,750
R21 · FY2023 · DA · contact PI
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial$212,563
R21 · FY2023 · AA · contact PI
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial$257,313
R21 · FY2022 · AA · contact PI
Developing and pilot testing a novel remotely delivered intensive outpatient program for individuals with opioid use disorder hospitalized with serious injection-related infections$185,073
R21 · FY2022 · DA · contact PI
Initiating substance use disorder treatment in hospitalized opioid use disorder patients$199,800
K23 · FY2021 · DA · contact PI
Initiating substance use disorder treatment in hospitalized opioid use disorder patients$199,800
K23 · FY2020 · DA · contact PI
Initiating substance use disorder treatment in hospitalized opioid use disorder patients$199,800
K23 · FY2019 · DA · contact PI
Initiating substance use disorder treatment in hospitalized opioid use disorder patients$199,800
K23 · FY2018 · DA · contact PI
Initiating substance use disorder treatment in hospitalized opioid use disorder patients$199,800
K23 · FY2017 · DA · contact PI